We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Seeks FDA Approval for Omicron Booster in Kids
Read MoreHide Full Article
Pfizer, Inc. (PFE - Free Report) and its partner BioNTech (BNTX - Free Report) have submitted a regulatory filing to the FDA, seeking to expand the emergency use authorization (EUA) granted to their bivalent BA.4/BA.5 Omicron-targeting COVID-19 vaccine.
This regulatory filing seeks label expansion for using the 10-µg booster dose of Pfizer/BioNTech’s bivalent COVID-19 vaccine in children aged five through 11 years. Currently, a 30-µg booster dose of this vaccine is authorized for usein individuals aged 12 years and older.
The bivalent vaccine contains 15-µg of an mRNA encoding the spike protein present in the original vaccine and 15 µg of an mRNA encoding the spike protein that is common in the Omicron BA.4 and BA.5 variants.
Pfizer/BioNTech’s filing seeking authorization for using the Omicron BA.4/BA.5 booster in kids is based on clinical studies on their bivalent Omicron BA.1-adapted vaccine as well as pre-clinical data from studies on their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine. However, unlike all previously-approved COVID-19 vaccines, the data on the bivalent booster shot is not supported by data from any human clinical studies demonstrating the vaccine’s effectiveness.
Pfizer/BioNTech have initiated clinical studies on the Omicron BA.4/BA.5-adapted bivalent vaccine, though the results will not be available before some months.
Shares of Pfizer have lost 25.8% in the year so far compared with the industry’s 5.6% decline.
Image Source: Zacks Investment Research
Pfizer/BioNTech also submitted a regulatory filing to the European Medicines Agency (“EMA”) seeking conditional marketing authorization (cMA) for their Omicron BA.4/BA.5-adapted bivalent vaccine in individuals aged 12 years and older. Earlier this month, the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the cMA for the bivalent vaccine. Pfizer/BioNTech also plans to submit an application to the EMA in the coming days to expand the cMA to include children aged 5 through 11 years.
Last month, the FDA granted EUA to Pfizer/BioNTech and Moderna’s (MRNA - Free Report) Omicron BA.4/BA.5-adapted bivalent vaccines for a single booster dose. The Pfizer/BioNTech and Moderna booster vaccines can be given at least two months following primary or booster vaccination. While Moderna’s Omicron booster is authorized for use in adults aged 18 years and older, Pfizer/BioNTech’s version is approved for people 12 and older.
These booster vaccines were developed at the FDA’s recommendation, issued back in June, to modify the design of their respective vaccine boosters to target the Omicron BA.4 and BA.5 subvariants.
In the past 60 days, estimates for Morphic’s 2022 loss per share have narrowed from $3.38 to $1.80. Loss estimates for 2023 have narrowed from $3.91 to $3.62 during the same period. Shares of Morphic have lost 46.7% in the year-to-date period.
Earnings of Morphic beat estimates in three of the last four quarters and missed the mark just once, witnessing a surprise of 48.29%, on average. In the last reported quarter, MORF delivered an earnings surprise of 183.95%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Pfizer (PFE) Seeks FDA Approval for Omicron Booster in Kids
Pfizer, Inc. (PFE - Free Report) and its partner BioNTech (BNTX - Free Report) have submitted a regulatory filing to the FDA, seeking to expand the emergency use authorization (EUA) granted to their bivalent BA.4/BA.5 Omicron-targeting COVID-19 vaccine.
This regulatory filing seeks label expansion for using the 10-µg booster dose of Pfizer/BioNTech’s bivalent COVID-19 vaccine in children aged five through 11 years. Currently, a 30-µg booster dose of this vaccine is authorized for usein individuals aged 12 years and older.
The bivalent vaccine contains 15-µg of an mRNA encoding the spike protein present in the original vaccine and 15 µg of an mRNA encoding the spike protein that is common in the Omicron BA.4 and BA.5 variants.
Pfizer/BioNTech’s filing seeking authorization for using the Omicron BA.4/BA.5 booster in kids is based on clinical studies on their bivalent Omicron BA.1-adapted vaccine as well as pre-clinical data from studies on their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine. However, unlike all previously-approved COVID-19 vaccines, the data on the bivalent booster shot is not supported by data from any human clinical studies demonstrating the vaccine’s effectiveness.
Pfizer/BioNTech have initiated clinical studies on the Omicron BA.4/BA.5-adapted bivalent vaccine, though the results will not be available before some months.
Shares of Pfizer have lost 25.8% in the year so far compared with the industry’s 5.6% decline.
Image Source: Zacks Investment Research
Pfizer/BioNTech also submitted a regulatory filing to the European Medicines Agency (“EMA”) seeking conditional marketing authorization (cMA) for their Omicron BA.4/BA.5-adapted bivalent vaccine in individuals aged 12 years and older. Earlier this month, the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the cMA for the bivalent vaccine. Pfizer/BioNTech also plans to submit an application to the EMA in the coming days to expand the cMA to include children aged 5 through 11 years.
Last month, the FDA granted EUA to Pfizer/BioNTech and Moderna’s (MRNA - Free Report) Omicron BA.4/BA.5-adapted bivalent vaccines for a single booster dose. The Pfizer/BioNTech and Moderna booster vaccines can be given at least two months following primary or booster vaccination. While Moderna’s Omicron booster is authorized for use in adults aged 18 years and older, Pfizer/BioNTech’s version is approved for people 12 and older.
These booster vaccines were developed at the FDA’s recommendation, issued back in June, to modify the design of their respective vaccine boosters to target the Omicron BA.4 and BA.5 subvariants.
Pfizer Inc. Price
Pfizer Inc. price | Pfizer Inc. Quote
Zacks Rank & Stocks to Consider
Pfizer currently carries a Zacks Rank #3 (Hold).A better-ranked stock in the overall healthcare sector is Morphic (MORF - Free Report) , which sports a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Morphic’s 2022 loss per share have narrowed from $3.38 to $1.80. Loss estimates for 2023 have narrowed from $3.91 to $3.62 during the same period. Shares of Morphic have lost 46.7% in the year-to-date period.
Earnings of Morphic beat estimates in three of the last four quarters and missed the mark just once, witnessing a surprise of 48.29%, on average. In the last reported quarter, MORF delivered an earnings surprise of 183.95%.